Albumin-corrected anion gap (ACAG) and mortality in GI bleeding
The albumin-corrected anion gap (ACAG) is a calculated laboratory parameter that adjusts the traditional anion gap (a measure of the difference between measured cations and anions in the blood) for serum albumin levels. Albumin is a negatively charged protein that significantly contributes to the anion gap; therefore, low albumin levels (commonly seen in critically ill patients) can lead to an underestimation of the anion gap. Correcting the anion gap for albumin levels provides a more accurate reflection of a patient's acid-base status, which is crucial for assessing critical illnesses, including gastrointestinal bleeding (GIB).
Role of ACAG in Mortality in GI Bleeding:
Recent research, including a retrospective cohort study analyzing data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, has demonstrated that ACAG is a powerful prognostic biomarker for predicting mortality in critically ill patients with gastrointestinal bleeding (GIB).
Key Findings:
- Association with Mortality:
- Elevated ACAG levels (≥20) were found to be independently associated with increased all-cause mortality in both short- and long-term follow-ups. This was confirmed through multivariable Cox proportional hazards regression analysis, with all results showing statistical significance (P < .001).
- Patients with higher ACAG levels had significantly lower survival rates compared to those with lower ACAG levels, as shown by Kaplan-Meier survival curves.
- Optimal Cutoff for Mortality Prediction:
- Using X-tile analysis, researchers identified an ACAG value of ≥20 as the optimal threshold for predicting 28-day mortality in GIB patients. This cutoff point allows clinicians to stratify patients into high-risk and low-risk categories.
- Predictive Accuracy:
- The study demonstrated that ACAG has moderate discriminative ability for mortality prediction, as evidenced by receiver operating characteristic (ROC) curves.
- A predictive nomogram model incorporating ACAG achieved strong performance, with area under the curve (AUC) values for 30-, 90-, 180-, and 365-day mortality all approximately 0.80. This indicates robust predictive accuracy for both short- and long-term outcomes.
- Consistency Across Subgroups:
- Subgroup analyses revealed that the prognostic value of ACAG remained consistent across diverse patient populations, further supporting its reliability as a universal risk marker in critically ill GIB patients.
- Linear Relationship with Mortality Risk:
- Restricted cubic spline models confirmed a linear relationship between increasing ACAG levels and higher mortality risk. This suggests that as ACAG rises, the likelihood of mortality increases proportionally.
Clinical Implications:
- Prognostic Biomarker: ACAG can serve as a reliable and independent biomarker for identifying critically ill GIB patients at higher risk of mortality.
- Risk Stratification: Incorporating ACAG into clinical risk assessment tools can enhance early identification of high-risk patients, allowing for timely and targeted interventions.
- Guidance for Treatment: By identifying patients with elevated ACAG, clinicians can prioritize aggressive management strategies to address underlying metabolic disturbances and improve patient outcomes.
Summary:
The albumin-corrected anion gap (ACAG) has emerged as a critical tool for predicting mortality in gastrointestinal bleeding. Elevated ACAG (≥20) is strongly associated with worse outcomes, including both short- and long-term mortality. Its integration into clinical practice could significantly improve risk stratification and guide the management of critically ill GIB patients.
